Citius Oncology, Inc. (NASDAQ: CTOR) Stock Competitors & Peer Comparison

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, RPRX has a market cap of 27B. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while RPRX trades at $60.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas RPRX's P/E ratio is 11.59. In terms of profitability, CTOR's ROE is -1.03%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CTOR is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check RPRX's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while CORT trades at $113.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas CORT's P/E ratio is 325.37. In terms of profitability, CTOR's ROE is -1.03%, compared to CORT's ROE of +0.08%. Regarding short-term risk, CTOR is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check CORT's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas WBA's P/E ratio is -1.64. In terms of profitability, CTOR's ROE is -1.03%, compared to WBA's ROE of -0.42%. Regarding short-term risk, CTOR is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check WBA's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, KNSA has a market cap of 6.1B. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while KNSA trades at $78.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas KNSA's P/E ratio is 88.67. In terms of profitability, CTOR's ROE is -1.03%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, CTOR is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check KNSA's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, LQDA has a market cap of 6B. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while LQDA trades at $67.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas LQDA's P/E ratio is 483.50. In terms of profitability, CTOR's ROE is -1.03%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CTOR is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check LQDA's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, PBH has a market cap of 2.5B. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while PBH trades at $52.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas PBH's P/E ratio is 11.87. In terms of profitability, CTOR's ROE is -1.03%, compared to PBH's ROE of +0.09%. Regarding short-term risk, CTOR is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check PBH's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, LTGO has a market cap of 1.5B. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while LTGO trades at $24.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas LTGO's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to LTGO's ROE of N/A. Regarding short-term risk, CTOR is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check LTGO's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas HROWL's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CTOR is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check HROWL's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas HROWM's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CTOR is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check HROWM's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, HELP has a market cap of 755M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while HELP trades at $12.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas HELP's P/E ratio is -2.92. In terms of profitability, CTOR's ROE is -1.03%, compared to HELP's ROE of -0.71%. Regarding short-term risk, CTOR is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check HELP's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas SVA's P/E ratio is -5.68. In terms of profitability, CTOR's ROE is -1.03%, compared to SVA's ROE of -0.01%. Regarding short-term risk, CTOR is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check SVA's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, CUVL has a market cap of 310.6M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while CUVL trades at $6.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas CUVL's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to CUVL's ROE of N/A. Regarding short-term risk, CTOR is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check CUVL's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, CELG-RI has a market cap of 244.7M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, CTOR is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check CELG-RI's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, HITI has a market cap of 220.6M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while HITI trades at $2.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas HITI's P/E ratio is -7.36. In terms of profitability, CTOR's ROE is -1.03%, compared to HITI's ROE of -0.43%. Regarding short-term risk, CTOR is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check HITI's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CTOR's ROE is -1.03%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CTOR is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check ATLN's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, SDEV has a market cap of 47.8M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while SDEV trades at $0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas SDEV's P/E ratio is -0.17. In terms of profitability, CTOR's ROE is -1.03%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, CTOR is more volatile compared to SDEV. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check SDEV's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas RAD's P/E ratio is -0.05. In terms of profitability, CTOR's ROE is -1.03%, compared to RAD's ROE of +2.76%. Regarding short-term risk, CTOR is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check RAD's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, NSRX has a market cap of 34.9M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while NSRX trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas NSRX's P/E ratio is -5.62. In terms of profitability, CTOR's ROE is -1.03%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, CTOR is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check NSRX's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CTOR's ROE is -1.03%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, CTOR is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check GLTO's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, SCYX has a market cap of 34M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while SCYX trades at $5.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas SCYX's P/E ratio is -1.58. In terms of profitability, CTOR's ROE is -1.03%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, CTOR is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check SCYX's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, CNSY has a market cap of 21M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while CNSY trades at $3.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas CNSY's P/E ratio is -0.42. In terms of profitability, CTOR's ROE is -1.03%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CTOR is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check CNSY's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, BFRI has a market cap of 20.4M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while BFRI trades at $1.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas BFRI's P/E ratio is -2.89. In terms of profitability, CTOR's ROE is -1.03%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CTOR is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check BFRI's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, SCNX has a market cap of 16M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while SCNX trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas SCNX's P/E ratio is -0.16. In terms of profitability, CTOR's ROE is -1.03%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, CTOR is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check SCNX's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, BFRIW has a market cap of 14.2M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while BFRIW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, CTOR's ROE is -1.03%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CTOR is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check BFRIW's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, COSM has a market cap of 12.2M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while COSM trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas COSM's P/E ratio is -0.30. In terms of profitability, CTOR's ROE is -1.03%, compared to COSM's ROE of -1.19%. Regarding short-term risk, CTOR is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check COSM's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CTOR's ROE is -1.03%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CTOR is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check CJJD's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas SSY's P/E ratio is -2.86. In terms of profitability, CTOR's ROE is -1.03%, compared to SSY's ROE of -0.09%. Regarding short-term risk, CTOR is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check SSY's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, POM has a market cap of 6.4M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while POM trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas POM's P/E ratio is -0.19. In terms of profitability, CTOR's ROE is -1.03%, compared to POM's ROE of +0.16%. Regarding short-term risk, CTOR is more volatile compared to POM. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check POM's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while BGMS trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas BGMS's P/E ratio is -0.25. In terms of profitability, CTOR's ROE is -1.03%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CTOR is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check BGMS's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, PAVS has a market cap of 4.1M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while PAVS trades at $4.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas PAVS's P/E ratio is -0.05. In terms of profitability, CTOR's ROE is -1.03%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CTOR is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check PAVS's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CTOR's ROE is -1.03%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CTOR is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check MDVL's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CTOR is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check ATNFW's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CTOR's ROE is -1.03%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CTOR is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check BGMSP's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CTOR's ROE is -1.03%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CTOR is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check AZNH's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CTOR's ROE is -1.03%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CTOR is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check LFLYW's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, PRPH has a market cap of 295.7K. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while PRPH trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas PRPH's P/E ratio is -0.01. In terms of profitability, CTOR's ROE is -1.03%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CTOR is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check PRPH's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, CPD has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas CPD's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to CPD's ROE of N/A. Regarding short-term risk, CTOR is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check CPD's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, POZN has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas POZN's P/E ratio is N/A. In terms of profitability, CTOR's ROE is -1.03%, compared to POZN's ROE of +0.61%. Regarding short-term risk, CTOR is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check POZN's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CTOR's ROE is -1.03%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CTOR is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check ESRX's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, OREX has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas OREX's P/E ratio is -0.14. In terms of profitability, CTOR's ROE is -1.03%, compared to OREX's ROE of -0.54%. Regarding short-term risk, CTOR is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check OREX's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CTOR's ROE is -1.03%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CTOR is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CTOR.Check SHPG's competition here

Citius Oncology, Inc. (NASDAQ: CTOR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CTOR stands at 72.1M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CTOR is priced at $0.78 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CTOR currently has a P/E ratio of -1.65, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CTOR's ROE is -1.03%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CTOR is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for CTOR.Check IPXL's competition here